BlueCrest Capital Management’s Galectin Therapeutics GALT Stock Holding History

BlueCrest Capital Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-45,280	Closed	-$231K	–	659
2019 Q1	$231K	Buy	45,280 +13,666	+43%	+$65.6K	0.01%	863
2018 Q4	$108K	Buy	+31,614	New	+$151K	0.01%	752
2018 Q2	–	Sell	-101,406	Closed	-$481K	–	1603
2018 Q1	$481K	Buy	+101,406	New	+$472K	0.02%	799

Other funds holding GALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlueCrest Capital Management's GALT Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2019, closing a stake of 45,280 shares — an estimated $231K sold.

BlueCrest Capital Management first reported a position in GALT in Q1 2018 and held it in 3 quarters. The position peaked at $481K in Q1 2018. 76 funds tracked by Wall St. Rank hold GALT as of Q2 2019.

BlueCrest Capital Management reported no remaining Galectin Therapeutics position as of Q2 2019 after selling out during the quarter.
BlueCrest Capital Management sold 45,280 Galectin Therapeutics shares in Q2 2019, an estimated $231K.
BlueCrest Capital Management first reported a position in Galectin Therapeutics in Q1 2018 and held it in 3 quarters.
BlueCrest Capital Management's Galectin Therapeutics position peaked at $481K in Q1 2018.
76 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.